The Relationship Between Arterial Stiffness and Pulmonary and Extrapulmonary Features in Ankylosing Spondylitis

August 10, 2025 updated by: Merve Firat, Kirsehir Ahi Evran Universitesi

Investigation of the Relationship Between Arterial Stiffness and Pulmonary and Extrapulmonary Features in Patients With Ankylosing Spondylitis

The aim of this study was to investigate the relationship between arterial stiffness and pulmonary and extrapulmonary features in patients with ankylosing spondylitis.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

25

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients followed up with a diagnosis of ankylosing spondylitis will be included.

Description

Inclusion Criteria:

  • Diagnosis of ankylosing spondylitis according to ASAS diagnostic criteria
  • Being aged 18-65
  • Stable medication use for at least 3 months
  • Voluntary participation in the study

Exclusion Criteria:

  • Having uncontrolled cardiopulmonary disease
  • Being pregnant
  • Having undergone recent surgery
  • Presence of malignancy
  • Failure to perform to assessments

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Ankylosing spondylitis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Arterial stiffness
Time Frame: 1st day
It will be evaluated with brachial pulse waves.
1st day
Respiratory muscle strength
Time Frame: 1st day
Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) will be measured using a portable mouth pressure device.
1st day
Respiratory muscle endurance
Time Frame: 1st day
This will be evaluated with increased workload testing.
1st day
Exercise capacity
Time Frame: 1st day
Exercise capacity will be assessed with 6 minute walk test.
1st day
Peripheral muscle strength
Time Frame: 1st day
Hand grip strength will be assessed with a grip dynamometer.
1st day
Muscle function
Time Frame: 1st day
It will be evaluated with one-minute sit to stand test
1st day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical activity
Time Frame: 1st day
Physical activity level will be evaluated using International Physical Activity Questionnaire-Short form
1st day
Forced vital capacity
Time Frame: 1st day
Forced vital capacity (FVC) will be assessed using spirometry.
1st day
Forced expiratory volume in one second
Time Frame: 1st day
Forced expiratory volume in one second (FEV1) will be assessed using spirometry.
1st day
Forced expiratory volume in one second/forced vital capacity ratio
Time Frame: 1st day
Forced expiratory volume in one second/forced vital capacity ratio will be assessed using spirometry.
1st day
Peak expiratory flow
Time Frame: 1st day
Peak expiratory flow (PEF) will be assessed using spirometry.
1st day
Forced mid-expiratory flow
Time Frame: 1st day
Forced mid-expiratory flow (FEF25-75) will be assessed using spirometry.
1st day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kirsehir Ahi Evran Universitesi

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 6, 2025

Primary Completion (Estimated)

January 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

November 27, 2024

First Submitted That Met QC Criteria

December 17, 2024

First Posted (Actual)

December 18, 2024

Study Record Updates

Last Update Posted (Actual)

August 12, 2025

Last Update Submitted That Met QC Criteria

August 10, 2025

Last Verified

November 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024-14/120

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ankylosing Spondylitis (AS)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe